John Hey

John Hey

Company: Alzheon

Job title: Chief Scientific Officer


Fluid & Imaging Biomarkers in ALZ-801 Development: A First-in-Class Oral Disease Modifying Agent for Alzheimer’s Disease 12:30 pm

Harnessing the power of fluid biomarkers and imaging modalities as diagnostic and theragnostic biomarkers in drug development for Alzheimer’s disease Revealing novel Alzheimer’s biomarkers used in modification trials and understanding their impact on disease modification trials Comparing and contrasting CSF versus plasma biomarkers on disease progression and severityRead more

day: Track B - Day 1 AM

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.